LY2605541

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2012-2016
024620122016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
INTRODUCTION Lack of control in diabetic patients has stimulated the development of new insulin analogues. One of these was basal… (More)
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2016
2016
The pharmacokinetics of LY2605541 (basal insulin peglispro), a novel long-acting basal insulin analogue, was evaluated in 5… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2014
2014
LY2605541 is a novel basal insulin analog with a prolonged duration of action. Two Phase I studies assessed LY2605541… (More)
Is this relevant?
2014
2014
AIMS To assess the pharmacokinetics (PK) and glucodynamics (GD) of LY2605541 in patients with type 2 diabetes mellitus. METHODS… (More)
Is this relevant?
2014
2014
AIMS The basal insulin analogue LY2605541, a PEGylated insulin lispro with prolonged duration of action, was previously shown to… (More)
Is this relevant?
2014
2014
OBJECTIVE To use continuous glucose monitoring (CGM) to evaluate the impact of the novel, long-acting basal insulin analog… (More)
  • table 1
Is this relevant?
Review
2014
Review
2014
There is a clinical rationale for a basal insulin with a predictable action and low inter- and intra-individual variability… (More)
Is this relevant?
2013
2013
OBJECTIVE To compare effects of LY2605541 versus insulin glargine on daily mean blood glucose as part of a basal-bolus regimen… (More)
Is this relevant?
2013
2013
We thank Professor Home for his interest (1) in our publication on a novel basal insulin analog, LY2605541 (2). Total, LDL, and… (More)
Is this relevant?
2012
2012
OBJECTIVE To evaluate whether LY2605541 results in lower fasting blood glucose (FBG) versus insulin glargine (GL). RESEARCH… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
Is this relevant?